The future of immuno-oncology in kidney cancer
In his keynote lecture at the American Society for Clinical [...]
New first-line treatment option for advanced kidney cancer available on the NHS
Today, the National Institute for Health and Care Excellence (NICE) have recommended tivozanib (Fotivda) [...]
NHS Cancer Vanguard partnering with pharma to improve patient experince
As part of NHS England's Five-Year Forward View and recent [...]
New drug shows promise in combination with cabozantinib for the treatment of advanced kidney cancer
Results from a phase 1 clinical trial looking at CB-839, [...]
Atezolizumab plus bevacizumab combination is positive for untreated metastatic kidney cancer
The combination of immunotherapy atezolizumab (Tecentriq) with targeted therapy bevacizumab [...]
Quality of life outcomes similar for cabozantinib and everolimus
Data from the phase 3 METEOR trial published in the Journal [...]
Britain fails to narrow the cancer survival gap behind the best in the world
A new global study involving 37 million cancer patients in [...]
Stereotactic ablative radiotherapy (SABR) is an effective treatment for primary kidney cancer
Data from a pooled analysis published in the journal Cancer [...]
Tessa Jowell’s moving speech calling for a change in the way the NHS treats cancer
Baroness Tessa Jowell received a standing ovation after delivering moving [...]
Improved cancer care results in over 2,000 more people surviving cancer in 2017
An NHS England press release, published on Christmas Eve, reports [...]
